Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals develops medicines for the treatment of intractable diseases, primarily in the United States. Its pipeline includes several RNAi-based therapeutics targeting various conditions. Plozasiran is in Phase 3 studies to reduce production of apolipoprotein C-III, while Zodasiran is in Phase 3 clinical trials to reduce angiopoietin-like protein 3. The company also has earlier-stage programs such as ARO-DIMER-PA, a dual functional RNAi molecule in Phase 1/2a trials, and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 trials. Additionally, Arrowhead is developing ARO-INHBE, ARO-ALK7, ARO-RAGE, ARO-MAPT, ARO-C3, and ARO-CFB, all in Phase 1/2a or Phase 1 clinical trials.

Arrowhead Pharmaceuticals is listed on the NasdaqGS exchange under the ticker symbol ARWR. The company is based in the United States and its stock is traded in US Dollars (USD). As a US-based company listed on a major American exchange, its financial reporting and share pricing are denominated in USD, making it accessible to investors using US currency.

Arrowhead Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. This means the company focuses on using biological processes and living organisms to develop therapeutic products. In Arrowhead's case, it specializes in RNA interference (RNAi) technology to create medicines for intractable diseases. Biotechnology companies like Arrowhead often engage in research and development of novel drugs, with a high emphasis on innovation and clinical trials.

Arrowhead Pharmaceuticals is headquartered in Pasadena, California, United States. The company primarily develops medicines for the treatment of intractable diseases in the United States. While its focus is on the US market, it has collaboration and license agreements with international partners such as GlaxoSmithKline Intellectual Property (No. 3) Limited, Takeda Pharmaceutical Company Limited, Amgen Inc., and Sarepta Therapeutics, Inc., indicating a global reach through partnerships.

Arrowhead Pharmaceuticals has a diverse pipeline of RNAi-based therapeutics. Notable late-stage programs include Plozasiran, which targets apolipoprotein C-III in Phase 3 studies, and Zodasiran, targeting angiopoietin-like protein 3 also in Phase 3. Earlier-stage programs include ARO-DIMER-PA (Phase 1/2a), ARO-PNPLA3 (Phase 1), ARO-INHBE (Phase 1/2a), ARO-ALK7 (Phase 1/2a), ARO-RAGE (Phase 1/2a), ARO-MAPT (investigational RNAi-based therapy), ARO-C3 (Phase 1/2a), and ARO-CFB (Phase 1/2a). These programs address a range of diseases by reducing the production of specific proteins.